Plateformes de biologie moléculaire en oncologie thoracique: quelles recherches, pour qui?

Fabrice Barlesi; Pascale Tomasini; Frédéric Fina; Véronique Secq; Laurent Greillier; Isabelle Nanni-Metellus; Stéphane Garcia; L'Houcine Ouafik

doi:10.1684/bdc.2013.1774

Plateformes de biologie moléculaire en oncologie thoracique: quelles recherches, pour qui?

Fabrice Barlesi, Pascale Tomasini, Frédéric Fina, Véronique Secq, Laurent Greillier, Isabelle Nanni-Metellus, Stéphane Garcia, L'Houcine Ouafik

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

1 Citation (Scopus)

Résumé

Management of NSCLC patients is more and more individualized especially on the base of bioguided treatments. In order to guarantee an access for all the patients too this type of strategy, the French NCI supports since 2006 a nationwide network of 28 regional genetics center. The financial support is based on public funds. The French NCI recommends today the assessment of seven biomarkers for all stage IV non squamous NSCLC patients. Due to financial and technical reasons, this recommendation must be followed. However, the molecular profiling of lung cancer patients would ideally be extended across all stages and all histological types of the disease in order to improve our knowledge in this field and provides the patient with an opportunity to access a bioguided treatment as frequently as possible.

Titre traduit de la contribution	Regional molecular genetics centers in thoracic oncology: What and who should be tested?
langue originale	Français
Pages (de - à)	737-741
Nombre de pages	5
journal	Bulletin du Cancer
Volume	100
Numéro de publication	7-8
Les DOIs	https://doi.org/10.1684/bdc.2013.1774
état	Publié - 1 janv. 2013
Modification externe	Oui

mots-clés

Bioguided treatment
French NCI
Lung cancer
Molecular genetics center
Molecular profiling
Personalized therapy

Accès au document

10.1684/bdc.2013.1774

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{02729753f41c4841905250af45420f9c,

title = "Plateformes de biologie mol{\'e}culaire en oncologie thoracique: quelles recherches, pour qui?",

abstract = "Management of NSCLC patients is more and more individualized especially on the base of bioguided treatments. In order to guarantee an access for all the patients too this type of strategy, the French NCI supports since 2006 a nationwide network of 28 regional genetics center. The financial support is based on public funds. The French NCI recommends today the assessment of seven biomarkers for all stage IV non squamous NSCLC patients. Due to financial and technical reasons, this recommendation must be followed. However, the molecular profiling of lung cancer patients would ideally be extended across all stages and all histological types of the disease in order to improve our knowledge in this field and provides the patient with an opportunity to access a bioguided treatment as frequently as possible.",

keywords = "Bioguided treatment, French NCI, Lung cancer, Molecular genetics center, Molecular profiling, Personalized therapy",

author = "Fabrice Barlesi and Pascale Tomasini and Fr{\'e}d{\'e}ric Fina and V{\'e}ronique Secq and Laurent Greillier and Isabelle Nanni-Metellus and St{\'e}phane Garcia and L'Houcine Ouafik",

year = "2013",

month = jan,

day = "1",

doi = "10.1684/bdc.2013.1774",

language = "Fran{\c c}ais",

volume = "100",

pages = "737--741",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "7-8",

}

TY - JOUR

T1 - Plateformes de biologie moléculaire en oncologie thoracique

T2 - quelles recherches, pour qui?

AU - Barlesi, Fabrice

AU - Tomasini, Pascale

AU - Fina, Frédéric

AU - Secq, Véronique

AU - Greillier, Laurent

AU - Nanni-Metellus, Isabelle

AU - Garcia, Stéphane

AU - Ouafik, L'Houcine

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Management of NSCLC patients is more and more individualized especially on the base of bioguided treatments. In order to guarantee an access for all the patients too this type of strategy, the French NCI supports since 2006 a nationwide network of 28 regional genetics center. The financial support is based on public funds. The French NCI recommends today the assessment of seven biomarkers for all stage IV non squamous NSCLC patients. Due to financial and technical reasons, this recommendation must be followed. However, the molecular profiling of lung cancer patients would ideally be extended across all stages and all histological types of the disease in order to improve our knowledge in this field and provides the patient with an opportunity to access a bioguided treatment as frequently as possible.

AB - Management of NSCLC patients is more and more individualized especially on the base of bioguided treatments. In order to guarantee an access for all the patients too this type of strategy, the French NCI supports since 2006 a nationwide network of 28 regional genetics center. The financial support is based on public funds. The French NCI recommends today the assessment of seven biomarkers for all stage IV non squamous NSCLC patients. Due to financial and technical reasons, this recommendation must be followed. However, the molecular profiling of lung cancer patients would ideally be extended across all stages and all histological types of the disease in order to improve our knowledge in this field and provides the patient with an opportunity to access a bioguided treatment as frequently as possible.

KW - Bioguided treatment

KW - French NCI

KW - Lung cancer

KW - Molecular genetics center

KW - Molecular profiling

KW - Personalized therapy

UR - http://www.scopus.com/inward/record.url?scp=84882977737&partnerID=8YFLogxK

U2 - 10.1684/bdc.2013.1774

DO - 10.1684/bdc.2013.1774

M3 - Article

C2 - 23823903

AN - SCOPUS:84882977737

SN - 0007-4551

VL - 100

SP - 737

EP - 741

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 7-8

ER -